Evidence map›Paper›PMID 11347970›Full record

ReviewFarmaco (Societa chimica italiana : 1989)

Structurally related nucleotides as selective agonists and antagonists at P2Y1 receptors.

K A Jacobson, S Moro, C Hoffmann, Y C Kim, H S Kim, R G Ravi, T K Harden, J L Boyer

Abstract readReview
In one paragraph

Review in Farmaco (Societa chimica italiana : 1989). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

K A JacobsonMolecular Recognition Section, LBC, NIDDK, National Institutes of Health, Bethesda, MD 20892-0810, USA. kajacobs@helix.nih.gov
S Moro
C Hoffmann
Y C Kim
H S Kim
R G Ravi
T K Harden
J L Boyer
National Institutes of Health · USUniversity of North Carolina at Chapel Hill · USUniversity of Padua · IT

Funding

PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDESZ01DK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$769k
Intramural NIH HHS Z01 DK031116Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

The P2Y1 receptor responds to adenine nucleotides and is present in platelets, heart, smooth muscles prostate, ovary, and brain. A selective antagonist may be useful as an antithrombotic agent. We have analyzed the binding site of this G protein-coupled receptor using ligand design, site-directed mutagenesis, and homology modeling based on rhodopsin. We have designed and synthesized a series of deoxyadenosine 3',5'-bisphosphate derivatives that act as antagonists, or, in some cases with small structural changes, as agonists or partial agonists. The 2-position accommodates Cl or thioethers, whereas the N6-position is limited to Me or Et. 2'-Substitution with OH or OMe increases agonist efficacy over 2'-H. Using molecular modeling of the binding site, the oxygen atoms of the ribose moiety were predicted to be non-essential, i.e. no specific H-bonds with the receptor protein appear in the model. We have, therefore, substituted this moiety with carbocylics, smaller and larger rings, conformationally constrained rings, and acyclics, with retention of affinity for the receptor. With simplified pharmacophores we are exploring the steric and electronic requirements of the receptor binding site, and the structural basis of receptor activation.

Indexed as

Binding SitesHumansMolecular ConformationNucleotidesPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Receptors, Purinergic P2Y1Structure-Activity RelationshipNucleotidesP2RY1 protein, humanPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Receptors, Purinergic P2Y1

Identifiers

PMID11347970
PMCPMC4313380
OpenAlexW2034898971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.